Pathologic Complete Response to Neoadjuvant Nivolumab/Ipilimumab in a Patient with Metastatic Renal Cell Carcinoma

Pathologic Complete Response to Neoadjuvant Nivolumab/Ipilimumab in a Patient with Metastatic Renal Cell Carcinoma

Nivolumab plus ipilimumab represents an effective combination of checkpoint inhibitors that can lead to a durable response with minimal toxicity in patients with metastatic renal cell carcinoma (mRCC). We present a case of a pathologic complete response to neoadjuvant nivolumab plus ipilimumab in a...

Full description

Bibliographic Details
Main Authors:	Taylor C. Peak, Elena M. Fenu, Michael B. Rothberg, Christopher Y. Thomas, Ronald L. Davis, Edward A. Levine
Format:	Article
Language:	English
Published:	Hindawi Limited 2020-01-01
Series:	Case Reports in Urology
Online Access:	http://dx.doi.org/10.1155/2020/8846135

Similar Items

Excellent Response to Nivolumab and Ipilimumab in Metastatic Gastroesophageal Junction Squamous Carcinoma
by: Narayanan Sadagopan, et al.
Published: (2019-01-01)

Nivolumab and Ipilimumab Combination Immunotherapy for Patients with Metastatic Collecting Duct Carcinoma
by: Tetsuya Danno, et al.
Published: (2021-01-01)

Efficacy and Safety of Nivolumab and Ipilimumab for Advanced or Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Cohort Study
by: Koji Iinuma, et al.
Published: (2021-04-01)

PRIME-HCC: phase Ib study of neoadjuvant ipilimumab and nivolumab prior to liver resection for hepatocellular carcinoma
by: David J. Pinato, et al.
Published: (2021-03-01)

Metastatic mucinous tubular and spindle cell carcinoma of the kidney responding to nivolumab plus ipilimumab
by: Hirotaka Fuchizawa, et al.
Published: (2021-09-01)

Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer
by: David Jones, et al.
Published: (2020-07-01)

Real World Outcomes of Ipilimumab and Nivolumab in Patients with Metastatic Melanoma
by: Nethanel Asher, et al.
Published: (2020-08-01)

Combination of nivolumab and ipilimumab in the treatment of disseminated renal cell carcinoma. Realities and prospects
by: B. Ya. Alekseev, et al.
Published: (2020-11-01)

Sequential Therapy with Nivolumab Followed by Ipilimumab Induces Complete Response in Metastatic Melanoma of the Lung but with Severe Hepatotoxicities
by: Sadanori Furudate, et al.
Published: (2016-10-01)

Onset of azoospermia in man treated with ipilimumab/nivolumab for BRAF negative metastatic melanoma
by: Matthew J. Rabinowitz, et al.
Published: (2021-01-01)

Ipilimumab and Nivolumab as First-Line Treatment of Patients with Renal Cell Carcinoma: The Evidence to Date
by: Sheng IY, et al.
Published: (2020-06-01)

Compassionate Use Program of Ipilimumab and Nivolumab in Intermediate or Poor Risk Metastatic Renal Cell Carcinoma: A Large Multicenter Italian Study
by: Antonuzzo, L., et al.
Published: (2022)

Pathological complete response after nivolumab therapy following angiogenesis inhibitors in a patient with metastatic renal cell carcinoma
by: Hiroki Hagimoto, et al.
Published: (2020-11-01)

Nivolumab and Ipilimumab in the Treatment of Metastatic Uveal Melanoma: A Single-Center Experience
by: Vidhya Karivedu, et al.
Published: (2019-01-01)

Cost-effectiveness of nivolumab plus ipilimumab as first-line therapy in advanced renal-cell carcinoma
by: Bin Wu, et al.
Published: (2018-11-01)

Healthcare cost comparison analysis of nivolumab in combination with ipilimumab versus nivolumab monotherapy and ipilimumab monotherapy in advanced melanoma
by: Ravi Potluri, et al.
Published: (2019-07-01)

A case of multiple metastatic sarcomatoid renal cell carcinoma with complete response to nivolumab
by: Masayuki Tomioka, et al.
Published: (2021-08-01)

Calcitriol-mediated hypercalcemia as an immune-related adverse event in a patient receiving nivolumab and ipilimumab for metastatic renal cell carcinoma, case report
by: Kai Johnson, et al.
Published: (2021-04-01)

Case Report: Complete Response of Recurrent and Metastatic Cystadenocarcinoma of the Parotid Gland With a Single Course of Combined Nivolumab and Ipilimumab Therapy
by: Yoshiyuki Nakamura, et al.
Published: (2021-02-01)

Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study
by: Kristina Navrazhina, et al.
Published: (2020-06-01)

Corrigendum to “Nivolumab and Ipilimumab in the Treatment of Metastatic Uveal Melanoma: A Single-Center Experience”
by: Vidhya Karivedu, et al.
Published: (2019-01-01)

Successful Treatment of Multiple Metastatic Melanoma with Nivolumab, Ipilimumab plus Denosumab Combined Therapy
by: Saaya Yoshida, et al.
Published: (2019-10-01)

Treatment of Metastatic Extramammary Paget Disease with Combination Ipilimumab and Nivolumab: A Case Report
by: Brendan John Guercio, et al.
Published: (2021-03-01)

Hypophysitis induced by ipilimumab and nivolumab combination therapy for advanced renal cell carcinoma: A case report
by: Aoi Motonaga, et al.
Published: (2021-09-01)

Long Term Remission and Cardiac Toxicity of a Combination of Ipilimumab and Nivolumab in a Patient With Metastatic Head and Neck Carcinoma After Progression Following Nivolumab Monotherapy
by: Katjana S. Schwab, et al.
Published: (2019-05-01)

Complete response to nivolumab for metastatic renal cell carcinoma on hemodialysis patient; a case report
by: Akito Ito, et al.
Published: (2020-01-01)

Severe Gastritis after Administration of Nivolumab and Ipilimumab
by: Yoshito Nishimura, et al.
Published: (2018-08-01)

Urticaria multiforme following nivolumab-ipilimumab therapy
by: Sonal Muzumdar, et al.
Published: (2020-06-01)

Correction: Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study
by: Charles Ferte, et al.
Published: (2020-07-01)

Aplastic anemia secondary to nivolumab and ipilimumab in a patient with metastatic melanoma: a case report
by: D. E. Meyers, et al.
Published: (2018-03-01)

Unmasking of intracranial metastatic melanoma during ipilimumab/nivolumab therapy: case report and literature review
by: Marin A. McDonald, et al.
Published: (2018-05-01)

Complete response to perioperative treatment using nivolumab for metastatic renal cell carcinoma: A case report
by: Daiki Ikarashi, et al.
Published: (2019-05-01)

Myocarditis and myasthenia gravis by combined nivolumab and ipilimumab immunotherapy for renal cell carcinoma: A case report of successful management
by: Takahiro Yanase, et al.
Published: (2021-01-01)

Potential biomarkers for nivolumab therapy of metastatic renal cell carcinoma
by: M. S. Sayapina, et al.
Published: (2018-04-01)

Autoimmune myositis and myasthenia gravis resulting from a combination therapy with nivolumab and ipilimumab for metastatic melanoma
by: Ravi Sutaria, et al.
Published: (2019-07-01)

PRISM protocol: a randomised phase II trial of nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced or metastatic renal cell carcinoma
by: Hannah L. Buckley, et al.
Published: (2019-11-01)

Ipilimumab and nivolumab/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors
by: Vikki Tang, et al.
Published: (2021-02-01)

Complete Pathologic Responses With Immunotherapy in Metastatic Renal Cell Carcinoma: Case Reports
by: Matthew D. Tucker, et al.
Published: (2020-12-01)

Complete response to ipilimumab and nivolumab therapy in a patient with extensive extrapulmonary high-grade small cell carcinoma of the pancreas and HIV infection
by: Muhammad Husnain, et al.
Published: (2018-07-01)

A case of dual-mechanism immune-related anaemia in a patient with metastatic melanoma treated with nivolumab and ipilimumab
by: Daniel J Olson, et al.
Published: (2020-06-01)

Cannot write session to /tmp/vufind_sessions/sess_tgs0u38k4cl5bnbao84ibub217